FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report
Executive Summary
FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future
You may also be interested in...
GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting
The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company
GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting
The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company
CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes
Last year, Virginia Behr, the ombudsman for FDA's Center for Drug Evaluation and Research, dealt with the usual consumer and industry complaints about off-label drug promotion, marketing of unapproved drugs and unethical research conduct. But she also played a greater role mediating scientific disputes between FDA staff